Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1541-1560 of 2,251 trials

B-Cell Lymphoma: TranspoCART19 T Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory B-cell lymphoma. The trial aims to evaluate the safety and effectiveness of this therapy in improving patient outcomes.

Relapsed or Refractory B-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Multiple Sclerosis: Ocrelizumab Serum Monitoring

We are studying how blood levels of ocrelizumab affect treatment outcomes in people with relapsing-remitting and primary progressive multiple sclerosis. This research may help personalize therapy and improve patient care.

Multiple Sclerosis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurology

OMX-0407 for Unresectable Solid Tumors

We are studying a new medication, OMX-0407, in patients with previously treated solid tumors to see how well it works and to find the safest dose. This trial will help us understand its effects on cancer response and patient quality of life.

Previously Treated Unresectable Solid Tumours>2 yearsSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Colon Cancer: New Treatment with PIPAC

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard treatments improves outcomes for patients with advanced colon cancer that has spread to the abdomen. This trial will help us understand its effects on survival and quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Small Cell Lung Cancer: 68Ga-EVG321 Diagnostic Study

We are studying a new diagnostic agent to see how it spreads in the body of patients with small cell lung cancer. The trial also looks at its safety and how the body processes it.

Small Cell Lung Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

T-Cell Acute Lymphoblastic Leukemia: OC-1 CAR T Therapy

We are studying the safety and effectiveness of OC-1 therapy for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoma. This trial aims to understand how well the treatment works and its impact on patient survival.

T-cell Acute Lymphoblastic LeukemiaT-cell Lymphoblastic Lymphoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

Anemia Treatment: Intravenous Iron for Surgery

We are studying whether intravenous iron can help patients with anemia undergoing surgery for lower limb artery disease. The aim is to see if it reduces the need for blood transfusions and improves recovery.

AnemiaMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyHematologyInternal Medicine

Rheumatoid Arthritis and Sjogren's Disease: Rapcabtagene Autoleucel Study

We are evaluating the safety of a new treatment for people with difficult-to-treat rheumatoid arthritis and severe Sjogren's disease. The study also looks at how the treatment works in the body.

Rheumatoid ArthritisSjogren's DiseaseSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Pancreatic Cancer: Durvalumab and Rintatolimod Combination

We are studying a new treatment combining durvalumab and rintatolimod for patients with metastatic pancreatic ductal adenocarcinoma. The goal is to see if this combination is safe and improves survival and quality of life.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesGastroenterologyOncology

Thyroid Cancer Treatment: Radioiodine Strategies

We are comparing two treatment strategies for intermediate-risk differentiated thyroid cancer patients to see which is more effective. This study will also evaluate patient quality of life and side effects over time.

Thyroid Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOncology

Sarcoidosis: Oral Sirolimus for Facial Skin Involvement

We are studying whether sirolimus can improve facial skin symptoms in patients with sarcoidosis. The trial also examines its effects on quality of life and overall skin health.

Skin Sarcoidosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesAllergologyDermatology

Hepatoblastoma and Hepatocarcinoma: Personalized Treatment Study

We are investigating new ways to tailor treatments for children with liver cancer to improve effectiveness and reduce side effects. This study also aims to better understand the genetic features of these tumors.

Hepatoblastoma and Liver CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Seminomas: EDEN Study on Reduced Therapy

We are testing a less intense treatment for patients with stage IIa/IIb seminomas under 3 cm to see if it helps prevent relapse. We’re also evaluating a biomarker to understand treatment response and its effects on quality of life.

Stage IIa/IIb Seminoma>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Oxygen Support Methods for High-Risk Patients

We are comparing non-invasive ventilation and high flow oxygen therapy for patients at high risk of needing reintubation. The goal is to see which method better helps patients recover and reduces complications.

Weaning Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicinePulmonology

Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease: CTX001 Treatment

We are studying a new gene therapy using modified stem cells for adolescents and adults with transfusion-dependent β-thalassemia or severe sickle cell disease. The goal is to evaluate its effectiveness and safety in improving their condition.

Transfusion-dependent β-thalassemiaSevere sickle cell disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematology

Plaque Psoriasis: Bimekizumab vs. Topical Corticosteroids

We are studying whether bimekizumab can better control plaque psoriasis compared to standard topical treatments. This trial aims to improve disease management and quality of life for patients.

Eruptive Psoriasis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatology

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Vaborem® for Serious Infections in Children

We are studying how Vaborem® is processed in the body and its safety in children with suspected or confirmed Gram-negative infections. This trial includes kids from birth to under 18 years old.

Acute Pyelonephritis≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics

Extensive-Stage Small-Cell Lung Cancer: THOR Trial

We are studying a combination of chemotherapy, pembrolizumab, and olaparib for patients with extensive-stage small-cell lung cancer. The goal is to see if this approach improves survival and response rates compared to standard treatments.

Extensive-Stage Small-Cell Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Advanced Respiratory Diseases: Inhaled Furosemide and Levodropropizine

We are studying whether inhaled furosemide can help reduce shortness of breath in patients with advanced respiratory diseases. We also want to see if adding oral levodropropizine enhances this effect.

Difficulty Breathing (Dyspnea)Efficacy phase (II)No PlaceboStandard MedicinesInternal MedicinePulmonology